Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Key findings from Phase I/II Study: fractionated Lu-177 PSMA therapy shows safety and promise

Scott Tagawa • 3 Jun 2024
ASCO 2024
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617

Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, presented key findings from a Phase I/II study (NCT03042468) on fractionated dose Lutetium-177 (Lu-177) PSMA therapy. The study demonstrated that dose escalation or higher doses of injected radioactivity are safe and effective. Additionally, the fractionated or dose-dense regimen showed promising activity in a PSMA-unselected, pretreated patient population. These results underscore the safety and potential efficacy of Lu-177 therapy in advanced prostate cancer. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Scott Tagawa

Evaluating adverse events related to 177Lu-PSMA-617 in PSMA-positive mHSPC
0:53
Evaluating adverse events related to 177Lu-PSMA-617 in PSMA-positive mHSPC
Scott Tagawa • 19 Oct 2025
Challenges in identifying patients suited for PSMA-targeted therapies in HSPC
1:24
Challenges in identifying patients suited for PSMA-targeted therapies in HSPC
Scott Tagawa • 19 Oct 2025
Dose-escalation and expansion study of 225Ac-J591 in mCRPC
2:47
Dose-escalation and expansion study of 225Ac-J591 in mCRPC
Scott Tagawa • 19 Oct 2025
PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC
2:08
PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC
Scott Tagawa • 19 Oct 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals